citalopram has been researched along with prazosin in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 3 (13.04) | 18.2507 |
| 2000's | 6 (26.09) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Sen, S; Sinha, N | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Maj, J; Rogóz, Z; Skuza, G; Sowińska, H | 2 |
| Maj, J; Rogóz, Z; Skuza, G | 1 |
| Aalto, J; Kiianmaa, K | 1 |
| Hilakivi, I; Kovala, T; Leppävuori, A; Shvaloff, A | 1 |
| Antkiewicz-Michaluk, L; Rokosz-Pelc, A; Vetulani, J | 1 |
| Arnt, J; Hyttel, J; Larsen, JJ | 1 |
| Arnt, J; Hyttel, J; Overø, KF | 1 |
| Platt, DM; Rowlett, JK; Spealman, RD | 1 |
| Cremers, TI; Folgering, J; Rea, K; Westerink, BH | 1 |
| Inoue, T; Koyama, T; Masuda, T; Nakagawa, S; Takamura, N | 1 |
| George, AK; Mann, RA | 1 |
| Buchanan, GF; Dayton, KG; Kruse, SW; Purnell, BS; Rosner, JI | 1 |
1 review(s) available for citalopram and prazosin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
22 other study(ies) available for citalopram and prazosin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The effect of antidepressant drugs on the locomotor hyperactivity induced by MK-801, a non-competitive NMDA receptor antagonist.
Topics: Animals; Antidepressive Agents; Benzazepines; Citalopram; Dizocilpine Maleate; Fluoxetine; Imipramine; Isomerism; Male; Maprotiline; Motor Activity; Prazosin; Rats; Rats, Wistar; Receptors, N-Methyl-D-Aspartate; Seizures; Sulpiride | 1992 |
Effects of MK-801 and antidepressant drugs in the forced swimming test in rats.
Topics: Animals; Antidepressive Agents; Citalopram; Depression; Dizocilpine Maleate; Haloperidol; Imipramine; Male; Mianserin; Motor Activity; Prazosin; Rats; Rats, Inbred Strains; Swimming | 1992 |
Antidepressant drugs increase the locomotor hyperactivity induced by MK-801 in rats.
Topics: Amitriptyline; Animals; Antidepressive Agents; Citalopram; Dizocilpine Maleate; Drug Interactions; Haloperidol; Imipramine; Male; Mianserin; Motor Activity; Prazosin; Rats; Rats, Inbred Strains | 1991 |
Role of brain monoaminergic systems in the increased ethanol drinking caused by REM-sleep deprivation.
Topics: 3,4-Dihydroxyphenylacetic Acid; Alcohol Drinking; Animals; Brain Chemistry; Catecholamines; Citalopram; Dopamine; Hydroxyindoleacetic Acid; Hypothalamus; Male; Methoxyhydroxyphenylglycol; Norepinephrine; Piperazines; Prazosin; Propylamines; Rats; Serotonin; Sleep Deprivation; Sleep, REM; Thiophenes | 1987 |
Effects of serotonin and noradrenaline uptake blockers on wakefulness and sleep in cats.
Topics: Animals; Cats; Citalopram; Electroencephalography; Indans; Male; Norepinephrine; Phentolamine; Prazosin; Propranolol; Propylamines; Serotonin Antagonists; Sleep; Sympatholytics; Wakefulness; Yohimbine | 1987 |
Chronic administration of antidepressant drugs increases the density of cortical [3H]prazosin binding sites in the rat.
Topics: Animals; Antidepressive Agents; Antipsychotic Agents; Binding Sites; Cerebral Cortex; Chlorprothixene; Citalopram; Imipramine; Male; Methotrimeprazine; Prazosin; Propylamines; Quinazolines; Rats; Rats, Inbred Strains; Spiperone | 1984 |
The citalopram/5-HTP-induced head shake syndrome is correlated to 5-HT2 receptor affinity and also influenced by other transmitters.
Topics: 5-Hydroxytryptophan; Amphetamine; Animals; Antipsychotic Agents; Behavior, Animal; Binding, Competitive; Brain; Citalopram; Female; Guinea Pigs; Histamine Antagonists; Humans; Hydroxydopamines; In Vitro Techniques; Male; Neurotransmitter Agents; Oxidopamine; Prazosin; Propylamines; Propylbenzilylcholine Mustard; Rats; Receptors, Adrenergic, alpha; Receptors, Dopamine; Receptors, Dopamine D2; Receptors, Muscarinic; Receptors, Serotonin; Serotonin Antagonists; Spiperone; Stereotyped Behavior | 1984 |
Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-uptake inhibitor, citalopram.
Topics: Amphetamines; Animals; Binding, Competitive; Brain Chemistry; Citalopram; Diet; Male; Membranes; Nerve Tissue Proteins; Prazosin; Propylamines; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Spiperone; Synaptosomes | 1984 |
Cocaine-like discriminative stimulus effects of heroin: modulation by selective monoamine transport inhibitors.
Topics: Animals; Carrier Proteins; Citalopram; Cocaine; Discrimination, Psychological; Dopamine Plasma Membrane Transport Proteins; Dopamine Uptake Inhibitors; Drug Interactions; Heroin; Male; Membrane Glycoproteins; Membrane Transport Proteins; Nerve Tissue Proteins; Neuropeptides; Norepinephrine Plasma Membrane Transport Proteins; Piperazines; Prazosin; Receptors, Adrenergic, alpha-1; Saimiri; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Symporters; Thiophenes; Vesicular Biogenic Amine Transport Proteins | 2004 |
Alpha1-adrenoceptors modulate citalopram-induced serotonin release.
Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibitors; Animals; Brain; Citalopram; Extracellular Space; Hippocampus; Imidazoles; Male; Morpholines; Prazosin; Prefrontal Cortex; Raphe Nuclei; Rats; Rats, Wistar; Reboxetine; Receptors, Adrenergic, alpha-1; Selective Serotonin Reuptake Inhibitors; Serotonin | 2010 |
The effects of the co-administration of the α₁-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Anti-Anxiety Agents; Citalopram; Conditioning, Psychological; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Fear; Male; Motor Activity; Prazosin; Rats; Rats, Sprague-Dawley; Selective Serotonin Reuptake Inhibitors; Stress, Psychological | 2012 |
Recurrent Priapism in a Military Veteran Receiving Treatment for PTSD.
Topics: Adult; Citalopram; Humans; Male; Methylphenidate; Prazosin; Priapism; Psychotropic Drugs; Stress Disorders, Post-Traumatic; Trazodone; Veterans | 2017 |
Effect of monoamine reuptake inhibition and α
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Citalopram; Duloxetine Hydrochloride; Electroshock; Fluoxetine; Male; Mice; Mice, Inbred C57BL; Norepinephrine; Prazosin; Reboxetine; Seizures; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin and Noradrenaline Reuptake Inhibitors; Sudden Unexpected Death in Epilepsy | 2019 |